RESEARCH

Evaluation of a diluted lipid emulsion solution as a lubricant for improved peripherally inserted central catheter guidewire removal in a neonatal population

Matheus F. P. T. van Rens1*, Ratheesh Paramban1, Airene L. V. Francia1, Prem Chandra2, Mohamad Adnan Mahmah1, Ulrich H. Thome3, Mohammad A. A. Bayoumi1 and Timothy R. Spencer4

Abstract

Background: Medical management of neonates is often established upon safe and reliable vascular access, frequently utilized to provide physiological monitoring, parenteral and supportive treatments, and diagnostic and/or procedural purposes. For this, peripherally inserted central catheters (PICCs) are often used to provide safe vascular access and infusion-related therapies in the neonatal intensive care (NICU) setting.

Purpose: Difficult PICC guidewire removal is understood to cause catheter damage, causing luminal rupture or possible breakage of the catheter or guidewire itself. The aim of this study was to assess and compare the incidence of therapy failures with use of a preflush fluid using normal saline (NSS) versus a diluted lipid solution (DLS) prior to device insertion, to assist with guidewire removal and prevent unnecessary catheter damage.

Method and setting: A retrospective, observational study was performed in the Neonatal Intensive Care Unit (NICU) of the Women’s Wellness and Research Centre, Hamad Medical Corporation, Qatar. This single site study included 507 neonates who required intravenous therapy administered via a PICC during the study period.

Results: Results demonstrated the use of a diluted lipid solution preflush (DLS) resulted in significantly lesser failures, when compared with the control group (NSS). This highlights a clinical significance after adjusting for day of insertion, gestational age, birth weight and catheter type.

Conclusion: DLS preflush demonstrated a benefit over the use of a NSS preflush to enhance PICC guidewire removal in neonatal patients in the NICU. The risk for development of maintenance-related complications leading to premature device removal decreased significantly if the DLS preflush was used. During the study period, no complications related to the use of a lipid preflush solution were identified.

Implications for practice and research: This may be the first study published investigating and supporting guidewire removal enhancement by using a diluted lipid/saline preflush solution. When the requirement for vascular access is most pertinent in the neonate, using a diluted lipid preflush may provide an effective method to assist in guidewire removal to prevent malposition and vascular device complications in the neonatal population.
Background
Medical management of neonates is often established upon safe and reliable vascular access needs. The need for safe and reliable vascular access may be related to physiological monitoring (arterial or central venous pressure), parenteral treatments (antibiotics, analgesia, inotropes), supportive therapy (intravenous nutrition, blood products administration, ECMO) and diagnostic or procedural purposes (power contrast injection for MRI/CT, cardiac catheterization) [1, 2]. Vascular access devices (VADs) such as peripherally inserted central catheters (PICCs) play a vital role in the management with this patient population.

Due to unique developmental characteristics, preterm infants are more susceptible to iatrogenic harm arising from vascular cannulation and its related complications. It is widely accepted that healthcare staff should take quality measures to prevent, detect, promptly treat, and mitigate any of these risks. Internationally, most neonatal units have implemented bundles of measures to reduce and manage risks associated with vascular access. One key element of these ‘care bundles’ is directed towards prevention of device-related complications, e.g., large catheters placed in small veins, associated pain from frequent replacement of peripheral cannulas, chemical-related vessel trauma from parenteral nutrition solutions or drugs that have irritant or vesicant properties [3].

In the neonatal intensive care (NICU) setting, PICCs have had reported complication rates between 0.05 to 3% [4]. Generally, PICCs are commonly associated with a reduced incidence of complications compared to short peripheral catheters [5]. Despite these advantages, PICCs may still be associated with complications such as device occlusion, infection, thrombosis, tip malposition, and potential catheter damage [4, 5], resulting in interrupted treatments, failed venous access and greater resource consumption with catheter replacement [6, 7].

Catheter damage, that causes leaking and embolization of the catheter itself, may be related to difficult guidewire removal during the insertion procedure, considering the nature of such small devices [8]. The inability to remove the guidewire possibly requires removing the device and reinserting a new catheter. The etiology of this phenomenon can be explained by a guidewire with approximately the same diameter as the actual inner diameter of the PICC, resulting in the wire sticking or getting caught up to the catheter’s internal wall. Despite generous pre-flushing of the catheter and guidewire using a normal saline solution (NSS) prior to insertion, removing the internal PICC guidewire once the device is in situ, can be challenging. Increased withdrawal resistance on removal of the guidewire, even after correct catheter tip position is confirmed by x-ray or ultrasound, may lead to tip malposition (tip will be pulled out of the superior vena cava/cav-atrial junction), but also potentially cause catheter leakage or breakage (shear or tearing forces on the wall of the catheter) [9]. Several interventions are described to decrease guidewire resistance during removal [8]. Reduction of any tension before attempting to remove the guidewire can be achieved by straightening and un twisting the parts of the PICC still outside the body [8]. In this study setting, it was reported that PICC guidewire removal-related complications occurred in 11/450 (2.4%) of all PICC insertions. Despite the relatively low numbers, the clinical impact to the patient of device malposition or damage must be considered. Recent evidence from large scale studies in neonatal populations regarding guidewire removal is lacking and largely absent.

A novel approach to overcome difficult guidewire removal is to use a diluted lipid solution (DLS) as a lubricant (Thome, personal correspondence) [10]. Although this has been used successfully in practice, particularly with intractable removals, there are potential safety concerns such as lipid emboli and risk of infection [11, 12]. Further empirical study is required to quantify these risks and until this evidence is available, this approach should be used with careful reflection and an established clinical benefit [8].

This study aims to highlight patient- (gestation, weight) and VAD characteristics (type, diameter and length) and assess the outcomes (guidewire removal, therapy failure) between conventional normal saline solution (NSS) and diluted lipid solution (DLS) as a lubricant to enhance difficult guidewire removal amongst a neonatal population.

Methods

Ethical approval
The study design and procedures (MRC-01-20-890) were approved by the local Institution Review Board (IRB). As the data source was anonymized, the local IRB committee determined the study an ‘observational chart review’ and that participant consent was not required.

Design and setting
A retrospective, cross-sectional study, using routinely collected anonymized intravenous device data was performed from January 2019 through July 2020. The primary outcome of interest was the occurrence of therapy
failure (e.g., leaking, breakage) in relation to PICC guide-wire removal leading to any unplanned device removal prior to completion of therapy. The study was performed in the 112-bed NICU of the Women's Wellness and Research Centre (WWRC) of Hamad Medical Corporation (HMC), Doha, Qatar.

Patient and public involvement statement
Study participants, nor parents were not involved in the design, conduct or reporting of this study. Retrospective data were retrieved from the electronic data management system of the facility.

Participants and sample size
Infants who were admitted to the NICU and who needed intravenous therapy through a 1Fr./28G or 2Fr./24G PICC were included in this study. Participants were excluded from the sample if the data collection was incomplete or whenever the data was related to the use of other devices e.g., peripheral IV catheters, umbilical venous catheters (UVC) or PICCs exceeding 2Fr./24G.

Procedure
During the patient assessment stage, the vascular access team follows a locally developed mnemonic, the “5Rs for Vascular Access” i.e., the Right device, for the Right vein, with the Right therapy, for the Right duration, for the Right patient, as described in a similar concept by Steere et al. [13] Venous cannulation is strictly performed under guidance of the local hospital policy, based on current evidence-based recommendations and guidelines [14, 15]. In this study setting, a PICC insertion is routinely performed by doctors and nurses from the neonatal vascular access team (neoVAT). The selection of appropriate veins are performed using near-Infra-Red (n-IR) technology for vein visualization (Christie Medical Holdings, Lake Mary, Florida, USA). In this facility’s practice, the choice for a central vascular access device is based upon the abovementioned 5Rs, with the required duration, fluid characteristics (pH and osmolarity) and patient characteristics (body weight and/or a known history of difficult vascular access). The 5Rs for Vascular Access-concept is represented in Fig. 1 and are based upon current standards of care [14, 15] and also considers product compatibility, hospital purchasing decisions and practitioner consensus.

All preflush solutions were prepared at the bedside, under sterile conditions. For the DLS, a 1 ml lipid 20% was diluted with 9 ml normal saline, the NSS was provided as prefilled 10 ml syringe flushes. Preflushes of NSS and DLS were provided alternated for the daily PICC insertions. Note: all PICCs were checked and flushed outside the patient and before the actual insertion procedure, to avoid excessive infusion of the preflush solution. Once the PICC was successfully inserted, the guidewire was then removed without any further flushing with either the NSS or DLS solutions. Total filling volumes of these PICC’s are extremely small and would vary between a maximum of 0.09-0.12 ml, depending on type and length of the device. During guidewire removal, a small amount of the DLS volume is removed due to adhesion of the fluid to the guidewire.

Measurements and data collection
Patients demographics and baseline data included sex, gestational age at birth in weeks and days, birth weight, and current body weight in grams. Data regarding the procedure of intravenous cannulation were the date and time of cannulation, including the number of attempts to successful cannulation, cannulated extremity, used type and size of vascular access device, indication for intravenous treatment, type of preflush used, any noted resistance during guidewire removal, date and time of PICC removal, total PICC dwell time in days, and the reason for PICC removal.

Statistical analyses
A total of 507 cases were retrospectively collected between January 2019 through to July 2020. Descriptive statistics were used to summarize and determine the sample characteristics and distribution of study participants data. The normally distributed data and results were reported with mean and standard deviation (SD); the remaining results reported with median and inter-quartile range (IQR). Categorical data were summarized using frequencies and proportions. Associations between two or more qualitative data variables were assessed using Chi-square ($\chi^2$) test or Fisher Exact test as appropriate. Quantitative data between the two independent groups were analyzed using unpaired t or Mann Whitney U test as appropriate. Univariate and multivariate logistic regression analysis (controlling and adjusted for potential predictors and confounders such as type of preflush, gender, resistance of the guidewire, days at insertion, birthweight, gestation at birth, number of attempts, extremity of cannulation, catheter characteristics, indication for intravenous therapy, indwell time) were applied to determine and assess the associations and predictive values of predictors and confounders stated above with binary outcome variable risk for failure of intravenous access devices. For multivariate logistic regression models, predictor variables were considered if statistical $P < 0.10$ level in univariate analysis or if determined a priori to be clinically important. The results of logistic regression analyses were presented as odds ratio (OR) with corresponding 95%
CI. Receiver operating characteristic curve (ROC) was computed and constructed to evaluate and assess predictive accuracy and discriminative ability of the developed logistic regression model (based on the predicted probabilities) using potential significant variables found in the multivariate logistic regression model. All \( P \) values presented were two-tailed, and \( P \) values < 0.05 was considered as statistically significant. All Statistical analyses were done using statistical packages SPSS version 27.0 (Armonk, NY: IBM Corp) and Epi-info (Centers for Disease Control and Prevention, Atlanta, GA) software.

**Results**

Study demographics as gender, age at PICC insertion, gestational age and birthweight, as well as chosen extremity for device insertion are presented in Table 1. The data demonstrated that 60.2% of patients received the DLS, and 39.8% received the NSS preflush. Most catheter insertions were in the lower extremities.
van Rens et al. BMC Pediatrics (2022) 22:71

(420/507; 82.8%) in both type of preflush solutions. The day of life on which the PICC insertion took place was an average of 7.61 days (± 17.0) with median 3 days (interquartile range 2 to 5) and there was no significant difference observed between both preflush groups. More detailed data regarding the type of flush showed a lower percentage in the NSS group for neonates 32-36wks gestation (NSS 16.3% vs DLS 19.3%) and in the birthweight category of 1500-2499 g (NSS 19.8% vs DLS 24.6%). However, this showed a reversed percentage for neonates with a birthweight > 2500 g (NSS 14.9% vs DLS 6.2%) and a gestational age of ≥ 37wks (NSS 12.4% vs DLS 6.6%).

A majority of all PICC (422/507; 83.2%) were inserted based on the required duration for extended total parenteral nutrition (TPN). The results of these insertion and catheter details are reflected in Table 2. The 1Fr./24G PICC were the most used type of catheter in the study population, accounted for (456/507; 91.7%) of all insertions. A first-time success (FTS) rate was observed in (361/507; 71.2%) and FTS was reported more frequently in the lipid solution group (224/361; 62.0%) vs the saline group (137/361; 38%).

For this study therapy failure related to the chosen type of preflush was observed. Table 3 shows a majority (401/507; 88.5%) of PICC were electively removed after the therapy was completed. When neonates were transferred to another hospital or expired (54/507; 10.7%), the team considered such cases as lost to follow up (local administrative censoring), these patients were excluded for therapy failure statistics. More successful or elective removals were within the DLS group (247/272; 90.8%) vs (154/181; 85.1%). All non-elective removals of PICCs occurred because of complications. Moreover, failure of therapy was more common in NSS group (27/181; 14.9%) than when using the DLS flush (25/272; 9.2%). The reasons of therapy failure like breaking or leaking of the PICC, catheter-related complications, extravasation or infiltration, and suspected sepsis were commonly reported in NSS group (22/181; 12.2%) vs (14/272; 5.2%), whereas complications due to maintenance and phlebitis were more frequently observed in the DLS group (11/305; 4.0%) vs (5/202; 2.8%).

Based on the results presented in Table 4, birthweight in grams, gestation in weeks, number of attempts and

| Table 1 Demographic Patient Factors |
|------------------------------------|
| **Type of Flush**                  |
|                                    |
| Total (n = 507)                     |
| Normal Saline (NSS) (n = 202)      |
| Diluted Lipid (DLS) (n = 305)      |
| P-value                            |
|                                    |
| Gender                             |
| Male                               |
| 277                                |
| 230                                |
| 125                                |
| 77                                 |
| 77                                 |
| 61.9%                              |
| 38.1%                              |
| 61.9%                              |
| 38.1%                              |
| 0.008*                             |
| Female                             |
| 230                                |
| 230                                |
| 125                                |
| 77                                 |
| 77                                 |
| 61.9%                              |
| 38.1%                              |
| 61.9%                              |
| 38.1%                              |
| 0.008*                             |
| Days of life at insertion          |
| Mean ± SD (median, IQR)            |
| 1-50 days                          |
| 490                                |
| 490                                |
| 197                                |
| 197                                |
| 96.9%                              |
| 97.5%                              |
| 96.9%                              |
| 97.5%                              |
| 0.770                              |
| 51-100 days                        |
| 13                                 |
| 13                                 |
| 3                                  |
| 3                                  |
| 2.6%                               |
| 1.5%                               |
| 2.6%                               |
| 1.5%                               |
| 0.770                              |
| 101-150 days                       |
| 3                                  |
| 3                                  |
| 1                                  |
| 1                                  |
| 0.6%                               |
| 0.5%                               |
| 0.6%                               |
| 0.5%                               |
| 0.0%                               |
| ≥ 151 days                         |
| 1                                  |
| 1                                  |
| 1                                  |
| 1                                  |
| 0.2%                               |
| 0.5%                               |
| 0.2%                               |
| 0.5%                               |
| 0.0%                               |
| GA at birth (days), Mean, SD       |
| ≤ 999 g                            |
| 133                                |
| 133                                |
| 49                                 |
| 49                                 |
| 26.2%                              |
| 24.3%                              |
| 26.2%                              |
| 24.3%                              |
| 0.052                              |
| 1000-1499 g                        |
| 210                                |
| 210                                |
| 83                                 |
| 83                                 |
| 41.4%                              |
| 41.1%                              |
| 41.4%                              |
| 41.1%                              |
| 0.026*                             |
| 1500-2499 g                        |
| 115                                |
| 115                                |
| 40                                 |
| 40                                 |
| 22.7%                              |
| 19.8%                              |
| 22.7%                              |
| 19.8%                              |
| 0.052                              |
| ≥ 2500 g                           |
| 49                                 |
| 49                                 |
| 30                                 |
| 30                                 |
| 9.7%                               |
| 14.9%                              |
| 9.7%                               |
| 14.9%                              |
| 0.052                              |
| Limb Extremity                     |
| Upper                              |
| 87                                 |
| 87                                 |
| 41                                 |
| 41                                 |
| 17.2%                              |
| 20.3%                              |
| 17.2%                              |
| 20.3%                              |
| 0.130                              |
| Lower                              |
| 420                                |
| 420                                |
| 161                                |
| 161                                |
| 82.8%                              |
| 79.7%                              |
| 82.8%                              |
| 79.7%                              |
| 0.052                              |

*IQR Inter-quartile range
### Table 2 Insertion and Catheter Details

| Type of Flush | Total (n = 507) | Normal Saline (NSS) (n = 202) | Diluted Lipid (DLS) (n = 305) | P-value |
|---------------|----------------|--------------------------------|-------------------------------|---------|
|               | n   | %    | n   | %    | n   | %    |             |         |
| Reason for Insertion |       |       |       |       |       |       |             |         |
| Antimicrobial Therapy | 17   | 3.4%  | 5    | 2.5%  | 12   | 3.9%  | 0.16        |         |
| PN Therapy      | 422  | 83.2% | 165  | 81.7% | 257  | 84.3% |             |         |
| Fluid characteristics | 23   | 4.5%  | 14   | 6.9%  | 9    | 3.0%  |             |         |
| Difficult Vascular Access | 45   | 8.9%  | 18   | 8.9%  | 27   | 8.9%  |             |         |
| Catheter Type   |       |       |       |       |       |       |             |         |
| 2 Fr. PICC 15 cm | 13   | 2.6%  | 6    | 3.0%  | 7    | 2.3%  | 0.139       |         |
| 2 Fr. PICC 30 cm | 29   | 5.7%  | 17   | 8.4%  | 12   | 3.9%  |             |         |
| 1 Fr. PICC 15 cm | 12   | 2.4%  | 7    | 3.5%  | 5    | 1.6%  |             |         |
| 1 Fr. PICC 20 cm | 296  | 58.4% | 111  | 55.0% | 185  | 60.7% |             |         |
| 1 Fr. PICC 30 cm | 157  | 31.0% | 61   | 30.2% | 96   | 31.5% |             |         |
| Number of attempts |       |       |       |       |       |       |             | 0.374   |
| 1              | 361  | 71.2% | 137  | 67.8% | 224  | 73.4% |             |         |
| 2              | 94   | 18.5% | 39   | 19.4% | 55   | 18.0% |             |         |
| 3              | 47   | 9.3%  | 23   | 11.4% | 24   | 7.9%  |             |         |
| 4              | 5    | 1.0%  | 3    | 1.5%  | 2    | 0.7%  |             |         |
| Guidewire resistance during removal |       |       |       |       |       |       | <0.001*     |         |
| Neutral        | 59   | 11.6% | 26   | 12.8% | 33   | 10.85 |             |         |
| Negative       | 358  | 70.5% | 87   | 43.1% | 271  | 88.9% |             |         |
| Positive       | 90   | 17.7% | 89   | 44.1% | 1    | 0.3%  |             |         |

*PN Parenteral nutrition; a based upon pH and osmolality; *-

### Table 3 Data Representing the Different Factors of VAD Removal

| Type of Flush | Total (n = 507) | Normal Saline (NSS) (n = 202) | Diluted Lipid (DLS) (n = 305) | P-value |
|---------------|----------------|--------------------------------|-------------------------------|---------|
|               | n   | %    | n   | %    | n   | %    |             |         |
| Reason for Removal |       |       |       |       |       |       |             |         |
| Administrative censoring | 54   | 10.7% | 21   | 10.4% | 33   | 10.8% | 0.260       |         |
| Therapy success (elective removal) | 401  | 88.5% | 154  | 85.0% | 247  | 90.8% |             |         |
| Therapy failureb     | 52   | 11.5% | 27   | 15.0% | 25   | 9.2%  |             |         |
| Breakage/leakage of material | 5    | 1.1%  | 4    | 2.2%  | 1    | 0.4%  |             |         |
| Catheter-related complicationsc | 14   | 3.1%  | 9    | 5.0%  | 5    | 1.8%  |             |         |
| Extravasation/Infiltration | 2    | 0.4%  | 1    | 0.6%  | 1    | 0.4%  |             |         |
| Maintenance-related complicationsd | 13   | 2.9%  | 4    | 2.2%  | 9    | 3.3%  |             |         |
| Phlebitis          | 3    | 0.7%  | 1    | 0.6%  | 2    | 0.7%  |             |         |
| Suspected sepsis   | 15   | 3.3%  | 8    | 4.4%  | 7    | 2.6%  |             |         |
| Dwell Time (days)  |       |       |       |       |       |       |             | 0.320   |
| Mean (SD)          | 12.97 ± 8.1 | 12.53 ± 8.2 | 13.26 ± 8.0 |         |

* Administrative censoring = death (other causes than CLABSI) and neonates transferred out. *For therapy failure administrative censoring is excluded

* Catheter related complications are defined as tip malposition, leaking, breakage of the catheter. *Maintenance related complications are defined as accidental removal and occlusion
| Variable                          | Therapy failure, n (%) | Unadjusted Odds ratio (OR) | 95% CI (for OR) | P-value |
|----------------------------------|------------------------|-----------------------------|-----------------|---------|
| Gender                           |                        |                             |                 |         |
| Female                           | 21 (10.2%)             | 1.0 (reference)             |                 |         |
| Male                             | 31 (12.5%)             | 1.25                        | 0.70, 2.25      | 0.454   |
| Type pre-flush                   |                        |                             |                 |         |
| Lipid (DLS)                      | 25 (9.2%)              | 1.0 (reference)             |                 |         |
| Normal saline (NSS)              | 27 (14.9%)             | 1.73                        | 0.97, 3.09      | 0.063   |
| Guidewire resistance during removal |                       |                             |                 |         |
| Neutral                          | 8 (16.7%)              | 1.0 (reference)             |                 |         |
| No resistance                    | 33 (10.1%)             | 0.56                        | 0.24, 1.30      | 0.178   |
| Resistance                       | 11 (14.1%)             | 0.82                        | 0.31, 2.12      | 0.696   |
| Birthweight (grams)              |                        |                             |                 |         |
| ≤ 999 g                          | 16 (13.6%)             | 1.0 (reference)             |                 |         |
| 1000-1499 g                      | 20 (10.4%)             | 0.74                        | 0.37, 1.50      | 0.403   |
| 1500-2499 g ≥2500 g              | 5 (4.9%)               | 0.33                        | 0.12, 0.93      | 0.036*  |
| ≥ 2500 g                         | 11 (26.8%)             | 2.34                        | 0.98, 5.57      | 0.055   |
| Gestation at birth (weeks)       |                        |                             |                 |         |
| 23-27 weeks                      | 15 (14.4%)             | 1.0 (reference)             |                 |         |
| 28-31 weeks                      | 21 (11.1%)             | 0.74                        | 0.36, 1.51      | 0.410   |
| 32-36 weeks                      | 5 (4.3%)               | 0.27                        | 0.09, 0.76      | 0.014*  |
| ≥ 37 weeks                       | 11 (25%)               | 1.98                        | 0.83, 4.74      | 0.126   |
| Number of attempts               |                        |                             |                 |         |
| 1                                | 31 (9.5%)              | 1.0 (reference)             |                 |         |
| 2                                | 14 (16.9%)             | 1.92                        | 0.97, 3.81      | 0.060   |
| 3                                | 5 (12.2%)              | 1.32                        | 0.48, 3.60      | 0.591   |
| 4                                | 2 (50.0%)              | 9.48                        | 1.29, 69.7      | 0.027*  |
| Side of cannulation              |                        |                             |                 |         |
| Left                             | 12 (11.1%)             | 1.0 (reference)             |                 |         |
| Right                            | 40 (11.6%)             | 1.05                        | 0.53, 2.08      | 0.891   |
| Extremity                        |                        |                             |                 |         |
| Lower extremity                  | 39 (10.3%)             | 1.0 (reference)             |                 |         |
| Upper extremity                  | 13 (17.3%)             | 1.82                        | 0.92, 3.61      | 0.085   |
| Catheter characteristics         |                        |                             |                 |         |
| 2 Fr. PICC 15 cm                 | 3 (27.3%)              | 1.0 (reference)             |                 |         |
| 2 Fr. PICC 30 cm                 | 6 (21.4%)              | 0.73                        | 0.15, 3.62      | 0.697   |
| 1 Fr. PICC 15 cm                 | 1 (9.1%)               | 0.27                        | 0.02, 3.08      | 0.290   |
| 1 Fr. PICC 20 cm                 | 29 (10.9%)             | 0.33                        | 0.08, 1.31      | 0.114   |
| 1 Fr. PICC 30 cm                 | 13 (9.4%)              | 0.28                        | 0.07, 1.18      | 0.082   |
| Indication for intravenous therapy|                       |                             |                 |         |
| Antimicrobial Therapy            | 2 (15.4%)              | 1.0 (reference)             |                 |         |
| TPN Therapy                      | 38 (10%)               | 0.61                        | 0.13, 2.87      | 0.534   |
| Fluid characteristics            | 5 (25%)                | 1.83                        | 0.30, 11.26     | 0.513   |
| Difficult Vascular Access        | 7 (17.1%)              | 1.13                        | 0.20, 6.28      | 0.887   |
| Indwell time catheter            |                        |                             |                 |         |
| ≤ 7 days                         | 23 (31.1%)             | 1.0 (reference)             |                 |         |
| > 7 to 14 days                   | 18 (7.4%)              | 0.18                        | 0.09, 0.35      | <0.001**|
| > 14 to 21 days                  | 7 (7.5%)               | 0.18                        | 0.07, 0.45      | <0.001**|
| > 21 to 27 days                  | 1 (4.8%)               | 0.11                        | 0.01, 0.88      | 0.057*  |
| > 27 days                        | 3 (15.0%)              | 0.39                        | 0.10, 1.47      | 0.164   |

CI: Confidence interval; * Significant at 0.05 level of significance; **significant at 0.01 level of significance
catheter dwell time have significant effect on the likelihood of failure of therapy. Results indicate that increasing birthweight $\geq 2500$ g and gestation at birth $\geq 37$ weeks were associated with an increased likelihood of failure of therapy. However, birthweight $1500-2499$ g (unadjusted OR $0.33; 95\%$ CI $0.12, 0.93, P=0.036$) and $32-36$-weeks of gestation (unadjusted OR $0.27; 95\%$ CI $0.09-0.76, P=0.014$) were found to be significantly associated with reduced risk of failure of therapy. Increasing time of the PICC in situ were observed to be significantly associated with a reduction in the likelihood of failure of therapy. The dwell time showed an inverse significant effect whereby the likelihood to failure was reduced when compared between $< 7$ to $27$ days. Specifically, $> 7$ to $14$ days (adjusted OR $0.09-0.35, P=0.001$), $> 14$ to $21$ days (adjusted OR $0.07-0.45, P=0.001$), and $> 21$ to $27$ days (adjusted OR $0.01-0.29, P=0.001$) demonstrated significant effect at risk of failure. The differences between the two types of preflush to the likelihood of failure of therapy was considered statistically significant at the $0.10$ level of significance.

Therefore, a computed prediction model was used to evaluate the discriminative ability of potentially significant predictors (observed in the developed multivariate logistic regression model) associated with risk of failure to therapy using ROC curve analysis. The value of area under the curve (AUC) observed was $0.757$ ($95\%$ CI $0.68, 0.83$), indicated that this developed regression model demonstrated an excellent fit (see Fig. 2).

| Table 5 | Multiple Logistic Regression Analyses with Factors Affecting the Risk for Failure of Intravenous Access Devices |
|---|---|
| Factors | Therapy failure n (%) | Adjusted Odds ratio (OR) | 95% CI for OR | P-value |
| **Gestation at birth (weeks)** | | | | |
| 23-27 weeks | 15 (14.4%) | 1.0 (reference) | | |
| 28-31 weeks | 21 (11.1%) | 0.53 | 0.24, 1.16 | 0.114 |
| 32-36 weeks | 5 (4.3%) | 0.12 | 0.04, 0.38 | $< 0.001^{*\ast\ast}$ |
| $\geq 37$ weeks | 11 (25%) | 0.61 | 0.21, 1.78 | 0.363 |
| **Indwell time catheter** | | | | |
| $\leq 7$ days | 23 (31.1%) | 1.0 (reference) | | |
| $> 7$ to $14$ days | 18 (7.4%) | 0.14 | 0.06, 0.30 | $< 0.001^{*\ast\ast}$ |
| $> 14$ to $21$ days | 7 (7.5%) | 0.10 | 0.04, 0.29 | $< 0.001^{*\ast\ast}$ |
| $> 21$ to $27$ days | 1 (4.8%) | 0.06 | 0.01, 0.49 | 0.009* |
| $> 27$ days | 3 (15.0%) | 0.21 | 0.05, 0.89 | 0.034* |

CI: Confidence interval; * Significant at 0.05 level of significance; **significant at 0.01 level of significance

| Table 6 | Association between CLABSI and Type of Pre-flush |
|---|---|
| Preflush Type | Lipid (DLS) | Saline (NSS) | P-value |
| CLABSI | Positive | 3 (1%) | 0 (0%) | 0.434* |
| | Negative | 302 (99%) | 202 (100%) | |

* Chi-Square-Fisher Exact test
Discussion

The external catheter diameters used in this study were 0.7 mm (1Fr.) and 1.1 mm (2Fr.) for devices used in this study, as documented on the product lid stock. The total priming volume varied from 0.09 ml to 0.12 ml, depending on the chosen catheter type and size (Vygon catheter product insert). The actual priming volume would be significantly less due to the guidewire size displacing an undetectable volume inside the PICC lumen (this was not measured during this study).

There may be elevated risk of PICC and infusion therapy failures within the clinical setting of the NICU, which may negatively affect a neonate’s treatment and outcomes [7]. Failure of therapy, resulting in premature removal, occurred in 54/453 (11.47%) of participants (transferred and death excluded), and a reported complication incidence rate of 7.91/1000 device days. The most frequently reported therapy failure prompting device removal was a catheter-specific complication (tip malposition, leaking, breakage of the catheter). The risk of catheter-related complications was reduced in patients with use of the DLS preflush for PICC guidewire removal. The normal and shear-and-tear forces between two opposing surfaces have been investigated and studies show that lipids may play a significant role [16]. Lower forces of friction may result in the reduction of shear-and-tear forces and its impact on the material of the catheter lumen itself. This study suggests that use of a DLS may reduce the coefficient of friction more effectively than NSS, resulting in reduced shear-and-tear related complications. Understanding the impact of frictional forces during guidewire removal is important with fragile, small bore vascular access devices, and further investigation is still needed to acknowledge the impact this may have on these devices.

Neonatal patients are an extremely vulnerable population. Vascular access devices provide the mainstay of all parenterally administered therapies for these, often-high-risk, patients. Reliability of PICC insertion and maintaining safe infusion therapy practices are paramount. While there are currently only NSS flushes available to clinicians, there remains a responsibility to explore other safe and effective alternatives for assisting guidewire removal in order to minimize complications.

Fig. 2 Receiver operating characteristic curve (ROC) to evaluate and assess predictive accuracy of the developed logistic regression model (using the predicted probabilities)

(Area under the curve-AUC = 0.757, 95% CI 0.68, 0.83)
Intravenous lipids may often provide a more ideal medium for microbial growth based upon their relatively neutral pH (pH=8) [17]. The infection prevention department at the study facility found no published evidence for not safely introducing use of a DLS during PICC guidewire removal. This study found that the reported CLABSI rate during the study period was not statistically significant between either groups and the microbiological safety with use of a DLS preflush to assist guidewire removal during PICC insertion in the NICU did not demonstrate or contribute to any negative infectious outcomes.

Strength and limitations
To the authors knowledge, this is the first study of this kind to evaluate the effect of a lipid-enhanced catheter preflush solution to assist PICC guidewire removal in the neonatal population worldwide. All eligible neonates were included during the study period, with the larger sample size representative of the facility’s neonatal PICC use. This helped increase the power of the study’s findings, helping to minimize any selection bias and increase the generalizability of the findings to similar settings.

Despite its strengths, this research also has some limitations. This study was a single center, retrospectively collected dataset, and in contrast to controlled randomized studies, this method creates risk of selection bias. During this study, every infant with a successfully inserted PICC was included to minimize the risk of selection bias. Data outcomes were not available for neonates transferred out of the facility. Although this number was relatively small, patients lost to follow-up may have differing outcomes than those who were included in this analyzed population. Nonetheless, future randomized control trails should focus on the continuous introduction of novel and clinically beneficial strategies to improve infusion therapy outcomes.

Conclusion
This study demonstrated a clinical benefit from the use of DLS preflush to enhance ease of PICC guidewire removal, reducing device-related complications and impacting the successful completion of infusion therapies. These included reduced risk of damage or rupture/ breakage to the lumen, catheter tip malpositions, and suspected sepsis. The risk for the development of maintenance-related complications leading to premature device removal was decreased significantly if the preflush DLS was used. The number of events for CLABSI rate were homogenous between the DLS and NNS groups, show no statistical significance. When the use of PICC is considered important for safe and reliable vascular access, DLS as a preflush for assisted guidewire removal offers a relatively safe and effective process in the neonatal population.

As only small amounts of lipid emulsion were used during this study, no other complications related to the use of a lipid emulsion were identified. Further research is still required. Secondary outcomes evaluating the cost effectiveness regarding the role and involvement of the pharmacy department and the nursing process of distributing and administering the diluted lipid solution may provide additional supportive evidence.

Identifying vascular access-related challenges for neonatal populations consistently requires innovation and clinical developments when trying to impact patient and vascular access device-related outcomes. The use of the DLS for PICC guidewire removal in these extremely small catheters is an important step for clinicians who place and care for vascular access devices in neonates.

Acknowledgments
The authors would like to thank and acknowledge all members of the nursing and medical staff of the NICU at WWRC for their assistance during the study period. We would like to thank Medical Research Center of the Hamad Medical Corporation for all their support in this research study. A special thanks to John Paul Ben Silang and Kalpana Singh for their support.

Authors’ contributions
MvR conceptualized and designed the study, coordinated, and supervised data collection, drafted the initial manuscript, and reviewed and revised the manuscript. RP was the primary investigator, drafted the initial manuscript and reviewed and revised the manuscript. MAM, MAAB, TRS and UT critically reviewed and edited the manuscript for important intellectual content. ALVF designed the data collection instruments, collected data, and reviewed and revised the manuscript. PC carried out the statistical analyses and also provided review of the manuscript. All authors approved the final manuscript as submitted.

Funding
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Availability of data and materials
The data that support the findings of this study are available from Matheus van Rens but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Matheus van Rens (rolandvanrens@icloud.com).

Declarations
Ethics approval and consent to participate
The study design and procedures (MRC-01-20-890) were approved by the local Institution Review Board (IRB). As the data source was anonymized, the local IRB committee determined the study an ‘observational chart review’ and that participant consent was not required. All methods were performed in accordance with the relevant guidelines and regulations.

Consent for publication
Not Applicable.
Competing interests
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. The local IRB made funds available to support open publication of this article.

All contributing authors declare no financial disclosures, conflicts, or competing interests in the development of this research. No industry funding, grants or sponsorship was received in the development of this research.

Author details
1 Neonatal Intensive Care Unit, Women’s Wellness and Research Center, Hamad Medical Corporation, Doha, Qatar. 2 Division of Neonatology, University Hospital for Children and Adolescents, Women’s and Children’s Hospital, Leipzig, Germany. 3 Global Vascular Access LLC, Scottsdale, AZ, USA.

Received: 28 October 2021   Accepted: 11 January 2022
Published online: 31 January 2022

References
1. Ainsworth SB, McGuire W. Peripherally inserted central catheters vs peripheral cannulas for delivering parenteral nutrition in neonates. JAMA. 2016;315(23):2612–3. https://doi.org/10.1001/jama.2016.7020.
2. Baillie CT Neonatal Vascular Access: In: Losty P, Flacke A, Rintala R, Huston J, Iwai N, editors. Richham’s neonatal surgery. London: Springer; 2018. https://doi.org/10.1007/978-1-4471-4721-3_9.
3. Ullman AJ, Bernstein SJ, Brown E, Aiyagari R, Doellman D, Faustino E, Gere B, Jacobs JP, Jaffray J, Kleidon T, Mahajan PV, McBride CA, Morton K, Pitts S, Prentice E, Rivald DC, Shaughnessy E, Stranz M, Wolf J, Cooper DS, Chopra V. The Michigan appropriateness guide for intravenous catheters in pediatrics: miniMAGIC. Pediatrics. 2020;145(Suppl 3):S269–84. https://doi.org/10.1542/peds.2019-3474.
4. Pettit J. Assessment of infants with peripherally inserted central catheters: part 1. Detecting the most frequently occurring complications. Adv Neonatal Care. 2002;2(6):304–15. https://doi.org/10.1016/S1551-6776(02)38626.
5. Pettit J. Assessment of the infant with a peripherally intravenous device. Adv Neonatal Care. 2003;3(5):230–40.
6. Moureau N. Impact and safety associated with accidental dislodgement of vascular access devices: a survey of professions, settings, and devices. J Assoc Vasc Access. 2018;23(4):203–15, ISSN 1552-8855. https://doi.org/10.1016/j.java.2018.07.002.
7. Yu X, Yue S, Wang M, Cao C, Liao Z, Ding Y, et al. Risk factors related to peripherally inserted central venous catheter nonselective removal in neonates. Biomed Res Int. 2018;2018:3769376. https://doi.org/10.1155/2018/3769376.
8. Hugill K, van Rens M. Inserting central lines via the peripheral circulation in neonates. Br J Nurs. 2020;29(19):S12–8. https://doi.org/10.12968/bjon.2020.29.19.S12.
9. Dong D, Niu F, Gao H, Yu M, Li Y, Xu L, et al. Influence of guide wire removal on tip location in peripherally inserted central catheters (PICCs): a retrospective cross-sectional study. BMJ Open. 2019;9(10):e027278. https://doi.org/10.1136/bmjopen-2018-027278.
10. Thorne UH. personal email communication. (2019, May 23)
11. Raman M, Almutairdi A, Mulesa L, Alberda C, Beattie C, Gramlich L. Parenteral nutrition and lipids. Nutrients. 2017;9(4):388. https://doi.org/10.3390/nu9040388.
12. Fresenius Kabi (2017, May 11). INTRALIPID® Lipid Injectable Emulsion. https://www.fresenius-kabi.com/en-ca/documents/Intralipid-PM-ENG.pdf.
13. Steere L, Picaca C, Davis M, Moureau N. (2019). Reaching one peripheral intravenous catheter (PICV) per patient visit with lean multimodal strategy: the PI5RightsTM bundle. J Assoc Vasc Access. 2019;24(5):31–43. https://doi.org/10.1033/019.2019.003.004.
14. Wyckoff M, Sharpe E. Peripherally Inserted Central Catheters: Guideline for Practice. 3rd ed, ed. N.A.O.N. Nurses. 2015.
15. Gorski LA, Hadaway L, Hagle ME, Broadhurst D, Clare S, Kleidon T, et al. Infusion therapy standards of practice, 8th. J Infus Nurs. 2021;44(15 Suppl 1):S1–S224. https://doi.org/10.1097/NAN.0000000000000396.
16. Panaser A, Tighe BJ. Function of lipids — their fate in contact lens wear: an interpretive review. Contact Lens Anterior Eye. 2012;35(3):100–11. https://doi.org/10.1016/j.jcle.2012.01.003.
17. Omran EA, Eisa FF, Bakh W. Microbial contamination of neonatal injectable lipid emulsions at 12 and 24 hours infusion time with evaluation of infection control measures. J Pediatr Pharmacol Ther. 2020;25(1):53–60. https://doi.org/10.5863/1551-6776-25.1.53.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.